VAXCYTE INC. DL -001
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more
VAXCYTE INC. DL -001 (5VA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, VAXCYTE INC. DL -001 (5VA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
VAXCYTE INC. DL -001 - Net Assets Trend (None–None)
This chart illustrates how VAXCYTE INC. DL -001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VAXCYTE INC. DL -001 (None–None)
The table below shows the annual net assets of VAXCYTE INC. DL -001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to VAXCYTE INC. DL -001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
VAXCYTE INC. DL -001 Competitors by Market Cap
The table below lists competitors of VAXCYTE INC. DL -001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Construction Partners Inc
NASDAQ:ROAD
|
$5.61 Billion |
|
Scout24 AG
PINK:SCOTF
|
$5.61 Billion |
|
Glacier Bancorp Inc
NYSE:GBCI
|
$5.61 Billion |
|
bioMérieux S.A
PINK:BMXMF
|
$5.61 Billion |
|
Orica Ltd
AU:ORI
|
$5.59 Billion |
|
Shin Kong Financial Holding Co Ltd
TW:2888
|
$5.59 Billion |
|
Ryman Hospitality Properties Inc
NYSE:RHP
|
$5.59 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
$5.59 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VAXCYTE INC. DL -001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares VAXCYTE INC. DL -001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently VAXCYTE INC. DL -001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares VAXCYTE INC. DL -001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $338,657,802
- Average return on equity (ROE) among peers: -66.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VAXCYTE INC. DL -001 (5VA) | €- | N/A | N/A | $5.60 Billion |
| 09R (09R) | $-2.13 Million | 0.00% | 0.00x | $10.61 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| Argen-X (1AE) | $4.10 Billion | -7.20% | 0.11x | $38.55 Billion |
| 1S90 (1S90) | $131.51 Million | -49.87% | 1.70x | $52.41 Million |
| Strategic Partners A/S (1TB0) | $19.25 Million | -1.55% | 0.22x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.50 Million |
| Intervacc AB (publ) (2E9) | $162.33 Million | -46.52% | 0.15x | $3.64 Million |
| 2F5 (2F5) | $-1.76 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $8.56 Million |